Peter MacCallum Cancer Centre welcomes the issuing of the first license to manufacture commercial T-Cell treatments, including breakthrough CAR T-Cell therapies, within Australia. The Therapeutic Goods Administration has awarded a T-Cells GMP manufacturing licence to Cell Therapies Pty Ltd, a company which is situated at Peter Mac.

Currently, the T-Cell based therapies approved for use in Australia require collecting blood from the patient, sending this off-shore for processing, before it is returned and reinfused into the patient.

“We are delighted to see the TGA has issued a license which would allow this process to be completed within Australia,” says Dr Michael Dickinson, who is the Deputy Director of the Centre of Excellence in Cellular Immunotherapy at Peter Mac.

“For hospitals like Peter Mac, on-shore processing would remove bottle-necks and risk of delay while patients can benefit from less time needed from blood collection to reinfusion.

“We look forward to the day when our patients are treated with CAR T-Cell products that are made in Australia.”

The issuing of this license confirms Melbourne has the required technical capability, and remains on-track to join a handful of sites in the US and Europe where these breakthrough T-Cell treatments are manufactured.

Cell Therapies Pty Ltd is an independent company which is majority owned by the Peter MacCallum Cancer Centre, and has supplied T-Cell based therapies for use at Peter Mac in the context of clinical trials.


For more information contact the Peter Mac Communications team on 0417 123 048.

About Peter Mac

Peter MacCallum Cancer Centre is one of the world’s leading cancer research, education and treatment centres globally and is Australia’s only public hospital solely dedicated to caring for people affected by cancer. We have over 2,500 staff, including more than 580 laboratory and clinical researchers, all focused on providing better treatments, better care and potential cures for cancer.

Additional Resources